The Patient Journey from Randomization to Detection of Prostate Cancer and Death: Results from ERSPC Rotterdam

Schröder, 2009, Screening and prostate-cancer mortality in a randomized European study, N Engl J Med, 360, 1320, 10.1056/NEJMoa0810084 Schröder, 2012, Prostate-cancer mortality at 11 years of follow-up, N Engl J Med, 366, 981, 10.1056/NEJMoa1113135 Schröder, 2014, Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up, Lancet, 384, 2027, 10.1016/S0140-6736(14)60525-0 Hugosson, 2019, A 16-yr follow-up of the European Randomized Study of Screening for Prostate Cancer, Eur Urol, 76, 43, 10.1016/j.eururo.2019.02.009 Osses, 2019, Results of prostate cancer screening in a unique cohort at 19yr of follow-up, Eur Urol, 75, 374, 10.1016/j.eururo.2018.10.053 Remmers, 2019, Predicting biochemical recurrence and prostate cancer-specific mortality after radical prostatectomy: comparison of six prediction models in a cohort of patients with screening- and clinically detected prostate cancer, BJU Int, 124, 635, 10.1111/bju.14790 Loeb, 2012, Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam, BJU Int, 110, 1678, 10.1111/j.1464-410X.2012.11367.x Schröder, 2012, Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC), Eur Urol, 62, 745, 10.1016/j.eururo.2012.05.068 Heidenreich, 2013, Early detection of prostate cancer: European Association of Urology recommendation, Eur Urol, 64, 347, 10.1016/j.eururo.2013.06.051 Remmers, 2020, Personalized strategies in population screening for prostate cancer, Int J Cancer, 147, 2977, 10.1002/ijc.33045 Van Poppel, 2021, Early detection of prostate cancer in 2020 and beyond: facts and recommendations for the European Union and the European Commission, Eur Urol, 79, 327, 10.1016/j.eururo.2020.12.010 Van Poppel, 2021, A European model for an organised risk-stratified early detection programme for prostate cancer, Eur Urol Oncol, 4, 731, 10.1016/j.euo.2021.06.006 Bhatt, 2021, A multistate survival model of the natural history of cancer using data from screened and unscreened population, Stat Med, 40, 3791, 10.1002/sim.8998 Gulati, 2012, The impact of PLCO control arm contamination on perceived PSA screening efficacy, Cancer Causes Control, 23, 827, 10.1007/s10552-012-9951-8 Shoag, 2016, Reevaluating PSA testing rates in the PLCO trial, N Engl J Med, 374, 1795, 10.1056/NEJMc1515131 Kerkhof, 2010, Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam), Int J Cancer, 127, 2639, 10.1002/ijc.25278 Roobol, 2003, Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands), BJU Int, 92, 48, 10.1111/j.1464-410X.2003.04390.x De Koning, 2003, Determining the cause of death in randomized screening trial(s) for prostate cancer, BJU Int, 92, 71, 10.1111/j.1465-5101.2003.04402.x Andersen, 2002, Multi-state models for event history analysis, Stat Methods Med Res, 11, 91, 10.1191/0962280202SM276ra Andersen, 2002, Competing risks as a multi-state model, Stat Methods Med Res, 11, 203, 10.1191/0962280202sm281ra Putter, 2007, Tutorial in biostatistics: competing risks and multi-state models, Stat Med, 26, 2389, 10.1002/sim.2712 de Wreede, 2011, mstate: an R package for the analysis of competing risks and multi-state models, J Stat Software, 38, 1, 10.18637/jss.v038.i07 Heijnsdijk, 2012, Quality-of-life effects of prostate-specific antigen screening, N Engl J Med, 367, 595, 10.1056/NEJMoa1201637 Donovan, 2016, Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer, N Engl J Med, 375, 1425, 10.1056/NEJMoa1606221 Lardas, 2017, Quality of life outcomes after primary treatment for clinically localised prostate cancer: a systematic review, Eur Urol, 72, 869, 10.1016/j.eururo.2017.06.035 Venderbos, 2017, Long-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer, Qual Life Res, 26, 1635, 10.1007/s11136-017-1507-7 Drost, 2018, Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study, Transl Androl Urol, 7, 98, 10.21037/tau.2017.12.28 Venderbos, 2021, Europa Uomo Patient Reported Outcome Study (EUPROMS): descriptive statistics of a prostate cancer survey from patients for patients, Eur Urol Focus, 7, 987, 10.1016/j.euf.2020.11.002 Buzzoni, 2015, Metastatic prostate cancer incidence and prostate-specific antigen testing: new insights from the European Randomized Study of Screening for Prostate Cancer, Eur Urol, 68, 885, 10.1016/j.eururo.2015.02.042 Wolters, 2010, The effect of study arm on prostate cancer treatment in the large screening trial ERSPC, Int J Cancer, 126, 2387, 10.1002/ijc.24870 Carlsson, 2019, Could differences in treatment between trial arms explain the reduction in prostate cancer mortality in the European Randomized Study of Screening for Prostate Cancer?, Eur Urol, 75, 1015, 10.1016/j.eururo.2019.03.010 European Commission. European Cancer Information System. Long term estimates of cancer incidence and mortality, 2022. https://ecis.jrc.ec.europa.eu/explorer.php?$0-4$1-All$4-1$3-34$6-0,85$5-2020,2040$7-7,8$21-0$CLongtermChart1_1$X0_-1-AE27$CLongtermChart1_2$X1_-1-AE27$CLongtermChart1_3$X2_-1-AE27$CLongtermChart1_4$X3_14-$X3_-1-AE27$CLongtermTable1_6$X4_-1-AE27.